Want to see KR:003000 full AI Analyst Report?
Top Page
Bukwang Pharmaceutical Co., Ltd.
(003000)
Select Model
Select Model
Rating:50Neutral
Price Target:
₩3,755.00
Action:N/A
Date:10/28/26
The score is held back primarily by weak TTM cash generation (negative free cash flow and poor cash conversion) and deteriorating margins despite a return to revenue growth and profitability. Technicals add pressure with the stock trading below key moving averages and negative MACD. Valuation is also a headwind due to a high P/E, partially offset by a ~3.33% dividend yield.
Positive Factors
Returning revenue growth
The return to 7.18% TTM revenue growth indicates that Bukwang is regaining commercial momentum after earlier volatility. Sustained sales expansion can strengthen operating scale, support product commercialization, and provide a foundation for rebuilding profitability over the coming quarters.
Negative Factors
Weak cash generation
Very low operating cash flow and negative TTM free cash flow show that reported earnings are not currently converting into sufficient cash. If this persists, Bukwang may have less flexibility to fund development, commercialization, or other investments without relying on additional financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Returning revenue growth
The return to 7.18% TTM revenue growth indicates that Bukwang is regaining commercial momentum after earlier volatility. Sustained sales expansion can strengthen operating scale, support product commercialization, and provide a foundation for rebuilding profitability over the coming quarters.
Read all positive factors
Bukwang Pharmaceutical Co., Ltd. (003000) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩369.99B
Dividend Yield3.33%
Average Volume (3M)302.86K
Price to Earnings (P/E)64.9
Beta (1Y)0.06
Revenue Growth22.17%
EPS Growth-38.54%
CountryKR
Employees650
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)60.36
Shares Outstanding98,664,670
10 Day Avg. Volume279,063
30 Day Avg. Volume302,860
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.09
Price to Sales (P/S)1.86
P/FCF Ratio33.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bukwang Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Bukwang Pharmaceutical Co., Ltd., a South Korean-based enterprise, conducts pharmaceutical operations both domestically and across international markets. The company manufactures a diverse array of pharmaceutical formats, encompassing oral solids,...
Bukwang Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
61
Positive
Balance Sheet
74
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 215.09B | 200.71B | 160.09B | 125.93B | 190.91B | 182.49B |
| Gross Profit | 98.70B | 95.72B | 74.34B | 50.05B | 79.43B | 75.76B |
| EBITDA | 16.75B | 19.65B | 7.63B | -31.47B | 4.89B | 11.40B |
| Net Income | 8.91B | 12.57B | -2.64B | -31.33B | -2.47B | -916.62M |
Balance Sheet | ||||||
| Total Assets | 467.05B | 502.17B | 373.18B | 429.02B | 400.93B | 397.42B |
| Cash, Cash Equivalents and Short-Term Investments | 169.10B | 216.21B | 130.09B | 151.23B | 85.52B | 84.28B |
| Total Debt | 80.67B | 80.34B | 79.42B | 79.39B | 930.79M | 1.56B |
| Total Liabilities | 132.66B | 161.24B | 129.03B | 194.75B | 129.08B | 117.36B |
| Stockholders Equity | 334.13B | 341.46B | 243.68B | 226.31B | 263.22B | 269.61B |
Cash Flow | ||||||
| Free Cash Flow | -4.45B | 11.15B | 31.75B | -13.32B | 11.47B | 25.74B |
| Operating Cash Flow | 3.39B | 18.48B | 34.36B | -10.50B | 16.46B | 26.52B |
| Investing Cash Flow | -50.38B | -95.68B | -27.73B | -2.32B | -3.15B | 4.75B |
| Financing Cash Flow | 74.53B | 82.76B | -67.65B | 76.84B | -10.40B | -27.48B |
Bukwang Pharmaceutical Co., Ltd. Technical Analysis
Negative
―
Price Trends
4033.80
Negative
4094.90
Negative
4890.20
Negative
Market Momentum
-79.36
Positive
41.64
Neutral
21.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:003000, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 3927.25, equal to the 50-day MA of 4033.80, and equal to the 200-day MA of 4890.20, indicating a bearish trend. The MACD of -79.36 indicates Positive momentum. The RSI at 41.64 is Neutral, neither overbought nor oversold. The STOCH value of 21.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:003000.
Bukwang Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₩560.29B | 5.53 | ― | 2.80% | 10.50% | 96.29% | |
60 Neutral | ₩404.42B | 8.96 | ― | 1.56% | -0.65% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ₩299.64B | 12.56 | ― | 1.57% | 5.50% | -26.11% | |
51 Neutral | ₩435.39B | -884.82 | ― | 0.08% | 6.21% | 95.65% | |
50 Neutral | ₩369.99B | 64.89 | ― | 3.33% | 22.17% | -38.54% | |
46 Neutral | ₩332.73B | -56.26 | ― | 2.01% | 15.38% | ― |
* General Sector Average
KR:003000
Bukwang Pharmaceutical Co., Ltd.
3,750.00
95.20
2.60%
KR:001060
JW Pharmaceutical Corporation
23,200.00
191.16
0.83%
KR:009290
Kwang Dong Pharmaceutical Co., Ltd.
6,370.00
567.55
9.78%
KR:019170
Shinpoong Pharmaceutical Co., Ltd.
8,460.00
-5,550.00
-39.61%
KR:170900
Dong-A ST Co., Ltd.
34,900.00
-8,968.36
-20.44%
KR:249420
Ildong Pharmaceutical Co., Ltd.
12,790.00
-10,206.94
-44.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.